Small molecule MASP-2 inhibitor - Omeros Corporation
Latest Information Update: 06 May 2024
At a glance
- Originator Omeros Corporation
- Class Small molecules
- Mechanism of Action MASP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified